iNFixion Bioscience announces effort to develop new NF1 monoclonal antibody
iNFixion Bioscience announced today its commitment to developing a new monoclonal antibody against NF1 protein. This NF1-specific reagent will be developed in rabbits using full-length NF1 protein as the immunogen, with the program goal being to establish a more sensitive and specific NF1 monoclonal antibody than is commercially available today. This NF1 research tool, once developed and validated, will be made available to the NF1 research community, on an at-cost basis. This work is being developed in partnership with Abterra Biosciences (previously Digital Proteomics) and is financially supported by a partial grant from the NF Therapeutics Acceleration Program (NTAP).